Stem cell-derived pancreatic islets are being studied as a rich transplantable source for insulin production, a therapeutic ...

TUCSON, AZ / ACCESS Newswire / April 29, 2025 / Retatrutide, also known as LY3437943, is an innovative triple receptor agonist targeting glucose-dependent insulinotropic polypeptide (GIP), ...

Doer Biologics begins patient dosing in phase 2 study of DR10624 to treat metabolic dysfunction-associated steatotic liver disease and MASH: Hangzhou, China Thursday, April 24, 20 ...

Wegovy and Zepbound, the two leading weight-loss drugs, together sold less than $5 billion in 2023, according to ...

The future of treating metabolic dysfunction–associated steatohepatitis (MASH) looks brighter than ever, says Naim Alkhouri, MD, as data emerges on newly developed interventions.

The Trump administration this month scrapped a Biden-era proposal that would have required state Medicaid programs and ...

Eli Lilly announced clinical trial results this week for a daily pill to treat obesity and diabetes. Its name is absolutely ...

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data from its Phase 2a clinical ...

Approximately two-thirds of patients responded to teduglutide, which is sold under the brand name Gattex as a treatment for ...

A new expert review endorses GLP-1 RAs and other medications for sustainable weight loss in children with obesity and MASLD.

Lexaria Bioscience (LEXX) provides a glucagon-like peptide-1 strategic update following important industry developments reported both by Pfizer ...

Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.